Tagrisso (Osimertinib): The 2032 Generic Opportunity Window

Tagrisso (osimertinib mesylate), AstraZeneca's blockbuster third-generation irreversible EGFR tyrosine kinase inhibitor ($6.58B in full-year 2024 global revenue, growing approximately 15% year-over-year, with over $2.5B in U.S. annual net sales), anchors an expansive future generic opportunity window. Approved for metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or L858R mutations, adjuvant post-resection therapy, and T790M resistance mutation disease, the U.S. market remains 100% brand-only today with zero generic osimertinib approved or commercially available. The primary statutory barrier protecting Tagrisso is its core pyrimidinediamine composition-of-matter patent, US Patent No. 8,946,235, which expires on August 8, 2032. Secondary patents covering methods of treatment (US 10,149,849) and dosing/formulations extend statutory exclusivity through 2035 to 2037. Leading Indian generic manufacturers including Alembic Pharmaceuticals Ltd., MSN Laboratories Private Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., and Dr. Reddy's Laboratories Ltd. maintain active Paragraph IV ANDA filings challenging listed patents. AstraZeneca resolved patent litigation against Alembic and MSN through confidential settlement agreements and consent judgments enjoining generic commercial launch prior to patent expiration, projecting the earliest generic entry window in August 2032.